PW Medtech Group (FRA:PWE) Earnings Yield %: 6.67% (As of Jul. 04, 2026)


FRA:PWE PW Medtech Group Ltd FRA:PWE
84 GF Score
Price €0.11
GF Value €0.12
! 6 Warning Signs
View Full Analysis

What is PW Medtech Group Earnings Yield %?

PW Medtech Group FRA:PWE -0.94% 84 Earnings Yield % is 6.67% as of Jul. 04, 2026. GuruFocus rates FRA:PWE with a GF Score™ of 84/100 and a GF Value™ of €0.12. The stock has 6 warning signs investors should review.

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2026-07-04), the stock price of PW Medtech Group is €0.105. PW Medtech Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01. Therefore, PW Medtech Group's earnings yield of today is 6.67%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. PW Medtech Group's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was -9.45%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


PW Medtech Group  (FRA:PWE) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.


PW Medtech Group Earnings Yield % Related Terms

FRA:PWE
84GF Score
PW Medtech Group Ltd FRA:PWE
Earnings Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PW Medtech Group Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

PW Medtech Group's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=0.007/0.105
=6.67 %

For company reported semi-annually, PW Medtech Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.007 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.

Frequently Asked Questions Learn more about Earnings Yield % →
What does a Earnings Yield % of 6.67% mean?
PW Medtech Group (FRA:PWE) has a Earnings Yield % of 6.67% as of Jul. 04, 2026. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on PW Medtech Group and its competitors.
Is PW Medtech Group's Earnings Yield % too high?
PW Medtech Group's current Earnings Yield % is 6.67%. Overall, PW Medtech Group has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's Earnings Yield % compare to ISRG and BDX?
PW Medtech Group's Earnings Yield % of 6.67% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield % for a Medical Devices & Instruments company?
A good Earnings Yield % depends on the Medical Devices & Instruments industry context. However, Earnings Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield % mean?
A high Earnings Yield % can signal that a stock is expensive relative to its fundamentals. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on PW Medtech Group and its competitors. PW Medtech Group's current Earnings Yield % is 6.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
PW Medtech Group (FRA:PWE) has a current Earnings Yield % of 6.67%. The stock's GF Value™ is €0.12, compared to a current price of €0.11 — trading 12.5% below its estimated fair value. The current Earnings Yield % is 6.67%. PW Medtech Group's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield % calculated?
Earnings Yield % is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current Earnings Yield % is 6.67% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PW Medtech Group (FRA:PWE) Overvalued in 2026?

Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued. The current stock price of €0.11 is trading 12.5% below its estimated GF Value™ of €0.12.

Key valuation signals for FRA:PWE:

  • Earnings Yield %: 6.67%
  • GF Value™: €0.12 vs. price of €0.11 (12.5% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PW Medtech Group Business Description

Other Exchanges 01358:Hong Kong
Address No. 23 Panlong West Road, Building 1, Pinggu District, Beijing, CHN, 101204
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
84GF Score

Get the complete analysis for FRA:PWE

Earnings Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.12
GF Value